topic manufacturing-nucleic-acids 
European Pharmaceutical Review
AUGUST 22, 2023
According to UK Research and Innovation ( UKRI ), £13 million is set to fund medicine manufacturing in the UK, through a focus on innovation in intracellular drug delivery, digitalisation and automation and nucleic acid medicines. This will overall increase the ease of manufacture and reduce costs.
Pharmaceutical Technology
JUNE 1, 2023
A new intracellular drug delivery centre will be established in the UK to support potential ribonucleic acid (RNA) vaccines and therapeutics , as well as the development of innovative drug delivery technologies. The funding is being provided under the agency’s Transforming Medicines Manufacturing programme.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
AUGUST 17, 2022
By self-circularisation, Orna’s oRNA technology makes circular ribonucleic acids (oRNAs) from linear RNAs. Topic sponsors are not involved in the creation of editorial content. These programmes will include therapies and vaccines in infectious disease and oncology areas.
European Pharmaceutical Review
DECEMBER 22, 2022
Advances in mRNA technologies and cellular delivery systems coupled with their cost effectiveness, manufacturing simplicity and ability to target previously-undruggable pathways has limitless potential that could revolutionise medicine. Manufacturing time for mRNA therapeutics is also fast compared to antibodies or protein-based drugs.
Pharmaceutical Technology
AUGUST 22, 2022
Porton Advanced Solutions has raised $80m in a Series B funding round to expand its end-to-end gene and cell therapy (GCT) contract development and manufacturing organisation (CDMO) platforms. By the end of this year or earlier next year, Porton will have a PD, AD and GMP manufacturing facility spread over more than 200,000ft² for GCT. .
Pharmaceutical Technology
MARCH 27, 2023
National Resilience will use the funding to establish a significant domestic biomanufacturing capacity and capabilities for vaccines, nucleic acids including mRNA, and biologics including antibodies, proteins and multi-specifics. Topic sponsors are not involved in the creation of editorial content.
Roots Analysis
AUGUST 15, 2023
These expression systems utilize bio machinery harvested from the lysate of disrupted cells for the manufacturing of a wide array of macromolecular and small molecule products. Overview of Cell Free Systems Cell-free systems are in-vitro platforms which allow occurrence of biochemical reactions in the absence of living cells.
Expert insights. Personalized for you.
85 
Let's personalize your content